Top Story

Orphan drug shows promise in Prader-Willi syndrome

March 28, 2015

Ten weeks of therapy with a diazoxide choline controlled-release tablet appeared to help control hyperphagia and reduce antisocial behaviors associated with Prader-Willi syndrome, according to a press release from the drug’s developer, Essentialis, Inc.

Diazoxide choline was granted orphan status for the treatment of Prader-Willi syndrome (PWS) by the FDA in May of last year.

In the Journals

Earlier assessment of fragility, fracture risk possible by gauging bone strength

March 27, 2015
Changes in bone strength may provide an earlier indication of treatment effects of glucocorticoid and anti-osteoporosis therapies compared with bone mineral density…
In the Journals

In adults with obesity, brain insulin action may be selectively impaired

March 27, 2015
The prefrontal cortexes of adults with overweight and obesity appear to have selectively impaired brain insulin action, possibly causing a modified homeostatic set point…
In the Journals

Anti-HCV seropositivity not associated with metabolic syndrome

March 27, 2015
Anti-hepatitis C virus infection seropositivity was not associated with metabolic syndrome among Taiwanese adults, regardless of age, gender and fibrosis, according to…
In the Journals

Fat distribution may influence mortality rates in men, women

March 27, 2015
The distribution of fat in the abdomen and thighs can have a significant effect on mortality in both men and women, according to research in the journal Obesity.Fat…
More News Headlines »
Obesity Consults

Obesity Consults: Volume 2, Number 5
Practical Guide to Medications Approved for Chronic Weight Management

Several pharmacologic options for the management of obesity have been approved by the US FDA, giving clinicians a range…
More »
Meeting News Coverage Video
thumbnail for video 4105100251001

VIDEO: Advocacy needed for best care at the right price

March 11, 2015
SAN DIEGO — Stephen Brietzke, MD, professor of medicine at the School of Medicine, University of Missouri Health…
More »
Obesity Consults: Volume 2, Number 2 Obesity Forum 2014 Highlights

Obesity Consults: Volume 2, Number 2
Obesity Forum 2014 Highlights

This activity is supported by educational grants from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc; Eisai, Inc.; Novo Nordisk; Vivus, Inc.

Management of obesity is complex, factoring in psychological, environmental, and physiologic causes. Treatment options…
More »
Current Issues
View the Current Issues